2A Pharm

2A Pharma is a clinical-stage biotechnology company headquartered in Aalborg, Denmark, with operations in Malmö, Sweden. The company focuses on developing next-generation prophylactic and therapeutic vaccines using its proprietary AAVLP (Adeno-associated virus-like particle) platform. This technology utilizes the capsid of the Adeno-associated virus (AAV) to display antigens in a dense, repetitive manner, inducing strong immune responses without the need for traditional adjuvants. Its lead program, 2AP01, is a broad-spectrum HPV vaccine targeting the conserved L2 protein, which has completed Phase 1 clinical trials. 2A Pharma's pipeline also includes candidates for oncology, such as EpCAM-targeting vaccines for head and neck cancer, and autoimmune conditions like vitiligo.